352 related articles for article (PubMed ID: 23678073)
21. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients.
Gliga S; Fiedler M; Dornieden T; Achterfeld A; Paul A; Horn PA; Herzer K; Lindemann M
Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33504093
[TBL] [Abstract][Full Text] [Related]
23. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
[TBL] [Abstract][Full Text] [Related]
24. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation.
Merindol N; Salem Fourati I; Brito RM; Grenier AJ; Charrier E; Cordeiro P; Caty M; Mezziani S; Malette B; Duval M; Alfieri C; Ovetchkine P; Le Deist F; Soudeyns H
J Immunol; 2012 Nov; 189(10):5016-28. PubMed ID: 23034171
[TBL] [Abstract][Full Text] [Related]
25. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.
Clari MÁ; Muñoz-Cobo B; Solano C; Benet I; Costa E; Remigia MJ; Bravo D; Amat P; Navarro D
Clin Vaccine Immunol; 2012 May; 19(5):791-6. PubMed ID: 22379065
[TBL] [Abstract][Full Text] [Related]
26. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
27. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.
Abate D; Fiscon M; Saldan A; Cofano S; Mengoli C; Sgarabotto D; d'Agostino C; Barzon L; Cusinato R; Toscano G; Feltrin G; Gambino A; Gerosa G; Palù G
J Clin Microbiol; 2012 Jun; 50(6):1974-80. PubMed ID: 22461674
[TBL] [Abstract][Full Text] [Related]
28. The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients.
Lindemann M; Korth J; Sun M; Xu S; Struve C; Werner K; Dornieden T; Horn PA; Witzke O; Wilde B
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544783
[TBL] [Abstract][Full Text] [Related]
29. Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice.
Solidoro P; Patrucco F; Boffini M; Rinaldi M; Airoldi C; Costa C; Cavallo R; Albera C
Ther Adv Respir Dis; 2020; 14():1753466620981851. PubMed ID: 33356914
[TBL] [Abstract][Full Text] [Related]
30. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
[TBL] [Abstract][Full Text] [Related]
31. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.
Kumar D; Chin-Hong P; Kayler L; Wojciechowski D; Limaye AP; Osama Gaber A; Ball S; Mehta AK; Cooper M; Blanchard T; MacDougall J; Kotton CN
Am J Transplant; 2019 Sep; 19(9):2505-2516. PubMed ID: 30768834
[TBL] [Abstract][Full Text] [Related]
32. Utility of the Interferon-Gamma Enzyme-Linked Immunosorbent Spot Assay to Predict Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.
Namsiripongpun W; Kantachuvesiri S; Bruminhent J
Transpl Int; 2023; 36():11527. PubMed ID: 38249787
[TBL] [Abstract][Full Text] [Related]
33. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
34. ELISPOT assay of interferon-γ secretion for evaluating human cytomegalovirus reactivation risk in allo-HSCT recipients.
Liang H; Xia J; Zhang R; Yang B; Wu J; Gui G; Huang Y; Chen X; Yang R; Wang H; Gong S; Fan J
J Med Virol; 2021 Nov; 93(11):6301-6308. PubMed ID: 34076905
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
37. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
38. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the T-cell response to human cytomegalovirus (HCMV) as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients.
Gabanti E; Lilleri D; Scaramuzzi L; Zelini P; Rampino T; Gerna G
New Microbiol; 2018 Jul; 41(3):195-202. PubMed ID: 30028473
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
